Cargando…

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)

Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS(G12C). We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the KRAS(G12C) mutation. MATERIALS AND METHODS: Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Sai-Hong Ignatius, Jänne, Pasi A., Leal, Ticiana A., Rybkin, Igor I., Sabari, Joshua K., Barve, Minal A., Bazhenova, Lyudmila, Johnson, Melissa L., Velastegui, Karen L., Cilliers, Cornelius, Christensen, James G., Yan, Xiaohong, Chao, Richard C., Papadopoulos, Kyriakos P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	RAPID COMMUNICATION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362872/ https://www.ncbi.nlm.nih.gov/pubmed/35167329 http://dx.doi.org/10.1200/JCO.21.02752

Ejemplares similares

Synthesis of Adagrasib (MRTX849), a Covalent KRAS(G12C) Inhibitor Drug for the Treatment of Cancer
por: Chen, Cheng-yi, et al.
Publicado: (2023)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
por: Negrao, Marcelo V., et al.
Publicado: (2023)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Speaker 3: John Krystal, USA
por: Krystal, John H., et al.
Publicado: (2016)

Speaker 4: John Krystal, USA
por: Krystal, John H., et al.
Publicado: (2016)

Evaluating the intracranial activity of adagrasib
por: Kotecha, Rupesh, et al.
Publicado: (2023)

A Multifactorial Interpretation of a Teenager’s Suicide: Based on Krystal’s Death in Casual Vacancy
por: Bahn, Geon Ho, et al.
Publicado: (2021)

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
por: Engstrom, Lars D., et al.
Publicado: (2023)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023)

Atropisomeric Racemization Kinetics of MRTX1719 Using Chiral Solvating Agent-Assisted (19)F NMR Spectroscopy
por: Kulyk, Svitlana, et al.
Publicado: (2022)

POS-849 CHARACTERISTICS AND OUTCOMES OF HOSPITALIZED COVID-19 PATIENTS WITH ACUTE KIDNEY INJURY
por: ESCUDERO, A.E., et al.
Publicado: (2022)

KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner
por: Laurent, Pierre-Antoine, et al.
Publicado: (2023)

849. Reduced CIED Infections with an Antibacterial Envelope: Microbiologic Analysis of the WRAP-IT Study
por: Sohail, Muhammad R, et al.
Publicado: (2019)

Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy
por: Issahaku, Abdul Rashid, et al.
Publicado: (2022)

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
por: Zhang, Yuchen, et al.
Publicado: (2022)

Altered lipid accumulation in Nannochloropsis salina CCAP849/3 following EMS and UV induced mutagenesis
por: Beacham, T.A., et al.
Publicado: (2015)

The Content and Nature of Narrative Comments on Swiss Physician Rating Websites: Analysis of 849 Comments
por: McLennan, Stuart
Publicado: (2019)

Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition
por: Cavaillé, Mathias, et al.
Publicado: (2020)

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023)

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS(G12D) Inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023)

849. Impact of a Combined Education and Data Driven Intervention on PrEP Uptake at the Veterans Health Administration
por: Musoke, Lewis, et al.
Publicado: (2021)

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
por: Ketcham, John M., et al.
Publicado: (2022)

849. Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates Reveals Diversity in Genetic Antibiotic Resistance Patterns
por: Beaver, Ryan, et al.
Publicado: (2020)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

P849: DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT.
por: Favasuli, V., et al.
Publicado: (2022)

849. Histopathology of Cutaneous Invasive Fungal Infections in a Tertiary Cancer Center: Causes, Discordance with Culture, and Histopathologic Determinants of Outcome
por: Gill, Pavandeep, et al.
Publicado: (2023)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Antibiotic Prophylaxis Protocols and Surgical Site Infection Rates in Trauma Surgery: A Prospective Regional Study of 26,849 Procedures.
por: Warnock, Michael, et al.
Publicado: (2019)

Proteomics analysis of the p.G849D variant in neurexin 2 alpha may reveal insight into Parkinson’s disease pathobiology
por: Cuttler, Katelyn, et al.
Publicado: (2022)

Platelet-derived growth factor receptor-β, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma
por: Suzuki, Shioto, et al.
Publicado: (2007)

Frameshift Mutations (Deletion at Codon 1309 and Codon 849) in the APC Gene in Iranian FAP Patients: a Case Series and Review of the Literature
por: Kashfi, Seyed Mohammad Hossein, et al.
Publicado: (2014)

Effect of ammonium and high light intensity on the accumulation of lipids in Nannochloropsis oceanica (CCAP 849/10) and Phaeodactylum tricornutum (CCAP 1055/1)
por: Huete-Ortega, María, et al.
Publicado: (2018)

Transgenic Expression of A Venous Malformation Related Mutation, TIE2-R849W, Significantly Induces Multiple Malformations of Zebrafish
por: Du, Zhong, et al.
Publicado: (2018)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017)

Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland
por: Sinikumpu, Suvi-Päivikki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pum05obh6s8d84qlaqce56bm3s